FMC Corp. (NYSE: FMC) is one of those companies where the honest answer to investment questions is: It depends on what you believe. The stock for this agricultural sciences company has fallen roughly 90% from its 2022 highs. The company carries heavy debt. Its flagship active ingredient, Rynaxypyr, a diamide insecticide that generates approximately $1.2 billion in annual revenue alongside Cyazypyr...
FMC Corp. (NYSE: FMC) is one of those companies where the honest answer to investment questions is: It depends on what you believe. The stock for this agricultural sciences company has fallen roughly 90% from its 2022 highs. The company carries heavy debt. Its flagship active ingredient, Rynaxypyr, a diamide insecticide that generates approximately $1.2 billion in annual revenue alongside Cyazypyr, is facing generic competition as key patents expire. That's a lot of bad news stacked there in one place. Continue reading
Bitcoin's Quantum Risk May Be Real, But the Network Is Preparing: Report Authored by Micah Zimmerman via BitcoinMagazine.com, Galaxy Digital’s latest report says the risk that quantum computing could compromise Bitcoin is real, but so is the work underway to protect the network. The firm’s research frames the issue as a long-term engineering and governance challenge rather than an imminent crisis,...
Bitcoin's Quantum Risk May Be Real, But the Network Is Preparing: Report Authored by Micah Zimmerman via BitcoinMagazine.com, Galaxy Digital’s latest report says the risk that quantum computing could compromise Bitcoin is real, but so is the work underway to protect the network. The firm’s research frames the issue as a long-term engineering and governance challenge rather than an imminent crisis, with developers already building tools that could reshape how the network secures trillions in value. At the center of the concern is a simple premise. Bitcoin relies on cryptographic signatures to prove ownership of coins. Those signatures, based on elliptic curve cryptography, are considered secure against classical computers. How Quantum Computing could break Bitcoin A sufficiently advanced quantum machine could break that assumption , allowing an attacker to derive a private key from a public one and spend funds without authorization. The scenario has a name within the industry: “Q-day,” the moment a cryptographically relevant quantum computer becomes viable. The timeline remains uncertain. Estimates range from years to decades, and no consensus exists among experts. The report stresses that uncertainty itself is the problem. Bitcoin’s decentralized structure means upgrades take time, often measured in years, not months. Still, the risk is uneven. Most Bitcoin is not exposed today. Wallets only reveal their public keys when funds are spent, meaning coins sitting untouched behind hashed addresses remain shielded. Vulnerability emerges in two main cases: coins whose public keys are already visible onchain, and coins in transit during a transaction. Which Bitcoin is actually at risk Galaxy cites estimates suggesting that millions of bitcoin could fall into the first category, including funds tied to early network activity and long-dormant wallets. These coins, often associated with early adopters and even the pseudonymous creator Satoshi Nakamoto, present a unique challen...
This is the most active start of the year in terms of tactical portfolio adjustments we've ever had at Inside Edge Capital with three separate reallocations. Our most recent was March 20, and we'll be sharing our three most important adjustments that I think may help you navigate these very tricky and range-bound markets. If you're a regular reader to this Tuesday column, you'll recall I posted a ...
This is the most active start of the year in terms of tactical portfolio adjustments we've ever had at Inside Edge Capital with three separate reallocations. Our most recent was March 20, and we'll be sharing our three most important adjustments that I think may help you navigate these very tricky and range-bound markets. If you're a regular reader to this Tuesday column, you'll recall I posted a bullish article citing market internals . We've become more cautious in light of recent events, and the rebalance I'll take you through reflects this. We not only reserve the right to change our minds, we require it as an active portfolio management for astute individual investors. Portfolio adjustment 1: We re-deployed index hedges The Nasdaq-100 is sitting right on top of a vulnerable shelf of support that I feel could quite possibly give way under the weight of mass uncertainty of geopolitical events and the knock on effect of interest rates and Fed policy. A break of NDX-100 ~24,000 could yield a breakdown to the 2024/2025 pivot level of approximately 22,500 and below there our recently adapted defensive posture will only increase. Our two flagship equity portfolios consist of individual names that we deem to be best in class within the 11 sectors that make up the S & P 500 . Below I've included the total percentage allocation of each sector along with the recently deployed hedges. In the more conservative Strategic Income & Growth (SIG) portfolio, that holds only dividend paying equities, we reduced our holdings most notably in materials, financials and technology. With that capital, we put 2% in the short-term treasury ETF (BIL) and 5% in the inverse NASDAQ QQQ ETF (PSQ) . If the Nasdaq goes down 1%, this ETF will be up 1% on the day. It's not meant to hedge the entire portfolio obviously, but we're looking to smooth the volatility on drawdowns and hopefully earn a return that will increase our buying power with the next leg higher in equities. In the more aggressive ...
chinaface/iStock via Getty Images TransAlta ( TAC ) up 6.5% in Tuesday's trading as National Bank Financial upgraded the Canadian power generator to Outperform from Sector Perform with a C$22 price target, saying the company has a number of catalysts ahead of it that can push the stock forward. The stock's recent 22% pullback no longer reflects the value of TransAlta's ( TAC ) upcoming phase 1 Kee...
chinaface/iStock via Getty Images TransAlta ( TAC ) up 6.5% in Tuesday's trading as National Bank Financial upgraded the Canadian power generator to Outperform from Sector Perform with a C$22 price target, saying the company has a number of catalysts ahead of it that can push the stock forward. The stock's recent 22% pullback no longer reflects the value of TransAlta's ( TAC ) upcoming phase 1 Keephills data center project, the US$600M Centralia gas conversion, or a recovery in Alberta power prices toward the mid-C$70s to mid-C$80s MWh range, National Bank analyst Patrick Kenny said. At its investor day on Monday, TransAlta ( TAC ) outlined a path to double-digit EBITDA growth through 2029, supported by 900-1,300 MW of expected Alberta net load growth that could push pool prices to $85-$120/MWh and drive EBITDA to $1.35B-$1.8B, Kenny noted. The anticipated increase in free cash flow and growing debt capacity should further support financial flexibility for TransAlta ( TAC ) to pursue a broad mix of greenfield, brownfield, and accretive M&A opportunities, the analyst said. More on TransAlta TransAlta Q4 2025 Earnings Call Presentation TransAlta: Canada's Powerhouse Of The Energy Transition TransAlta: Taking Profit Never Hurt Anyone
Zerbor/iStock via Getty Images ADMA Biologics ( ADMA ) fell 15% amid a short report from Culper Research. Culper Research disclosed that it's short shares of ADMA Biologics ( ADMA ). ADMA ( ADMA ) didn't immediately respond to Seeking Alpha's email request for comment. More on ADMA Biologics ADMA Biologics, Inc. (ADMA) Q4 2025 Earnings Call Transcript ADMA Biologics: Business Update And My Price T...
Zerbor/iStock via Getty Images ADMA Biologics ( ADMA ) fell 15% amid a short report from Culper Research. Culper Research disclosed that it's short shares of ADMA Biologics ( ADMA ). ADMA ( ADMA ) didn't immediately respond to Seeking Alpha's email request for comment. More on ADMA Biologics ADMA Biologics, Inc. (ADMA) Q4 2025 Earnings Call Transcript ADMA Biologics: Business Update And My Price Target ADMA Biologics, Inc. (ADMA) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript ADMA Biologics announces $125M accelerated share repurchase with JPmorgan ADMA forecasts $635M revenue for 2026 as ASCENIV drives margin expansion and new supply deals extend growth runway
Microsoft (NASDAQ:MSFT) stock is sliding approximately 2% to 3% in Tuesday trading, with shares hovering around $374. These are quiet-looking numbers on the surface, but for a company this closely watched, they carry weight. The decline is unfolding even as Bank of America (NYSE:BAC) reinstated coverage of Microsoft shares with a Buy rating and a ... Microsoft Slips as OpenAI Bet Starts to Worry I...
Microsoft (NASDAQ:MSFT) stock is sliding approximately 2% to 3% in Tuesday trading, with shares hovering around $374. These are quiet-looking numbers on the surface, but for a company this closely watched, they carry weight. The decline is unfolding even as Bank of America (NYSE:BAC) reinstated coverage of Microsoft shares with a Buy rating and a ... Microsoft Slips as OpenAI Bet Starts to Worry Investors
The Israeli military estimates it would need several more weeks of fighting to complete its war goals in Iran, at a time when President Trump says the U.S. is negotiating an end to the war. (Image credit: AFP via Getty Images)
The Israeli military estimates it would need several more weeks of fighting to complete its war goals in Iran, at a time when President Trump says the U.S. is negotiating an end to the war. (Image credit: AFP via Getty Images)
Piyaphorn Promnonsri/E+ via Getty Images Thesis Protalix BioTherapeutics, Inc. ( PLX ) for FY25 reported a lot weaker-than-expected results. GAAP EPS was a loss of $0.08, missing the consensus by about $0.07, with revenue reaching $52.7 million. Revenue was down just 1% year over year but missed expectations by about $5.2 million. So there were much softer sales, but also some hefty pipeline inves...
Piyaphorn Promnonsri/E+ via Getty Images Thesis Protalix BioTherapeutics, Inc. ( PLX ) for FY25 reported a lot weaker-than-expected results. GAAP EPS was a loss of $0.08, missing the consensus by about $0.07, with revenue reaching $52.7 million. Revenue was down just 1% year over year but missed expectations by about $5.2 million. So there were much softer sales, but also some hefty pipeline investments. Now, despite this miss, the company still issued a pretty strong FY26 guidance of $78 to $83 million, well above consensus, which was at $71.8 million. I think we can put this down to an Elfabrio milestone and some strong expected commercial growth on the back of the European approval. My upside would then come from faster-than-expected Elfabrio adoption, with the new driver being the E4W dosing advantage, as I'll explain. This should positively impact Chiesi's revenues and improve the overall margin. I also see some additional upside potentially coming from a U.S. dosing approval or strong PRX-115 data. Protalix BioTherapeutics, Inc. FY25 Earnings Overview Back in 2024, we did see some short-term profitability from Protalix; however, 2025 is more reflective of investment-driven losses. Total revenue came in at $52.7 million, only slightly down from $53.4 million in FY24, and primarily due to a decline in sales to its partner Chiesi. The good news was that the drop was partially offset by a much stronger demand from Pfizer for Elelyso supply needs. We also saw stable contributions from Brazil’s Fiocruz. As for the overall revenue mix, it’s still very much dependent on product sales rather than high-margin licensing income, the latter of which remained rather minimal. What also didn't make for great viewing was the fact that the cost of goods sold rose about 11%, so again, this would indicate margin pressure, mostly from production scale and partner mix. So if we take that combination of flat revenue and rising costs, it compressed operating performance. As a result,...
Marco Rubio welcomes release of Dennis Coyle, who was detained in January last year for violating unspecified laws Afghanistan’s Taliban authorities have released American academic Dennis Coyle after holding him for over a year, with the foreign ministry saying the release came on the occasion of Eid al-Fitr, the Muslim holiday that marks the end of the Islamic holy month of Ramadan. A statement f...
Marco Rubio welcomes release of Dennis Coyle, who was detained in January last year for violating unspecified laws Afghanistan’s Taliban authorities have released American academic Dennis Coyle after holding him for over a year, with the foreign ministry saying the release came on the occasion of Eid al-Fitr, the Muslim holiday that marks the end of the Islamic holy month of Ramadan. A statement from the ministry said the academic researcher had been released in Kabul on Tuesday, following an appeal from his family and after Afghanistan’s supreme court “considered his previous imprisonment sufficient”. Continue reading...
Shares of customer relationship management and data software giant Salesforce, Inc. (NYSE: CRM) fell hard on Tuesday, down 5.8% as of 1:37 p.m. EDT. There wasn't any company-specific news for Salesforce, but the entire enterprise software segment was down harshly today. This was likely due to a new update to Anthropic's agentic tool, which can now complete tasks on one's computer. The fear is that...
Shares of customer relationship management and data software giant Salesforce, Inc. (NYSE: CRM) fell hard on Tuesday, down 5.8% as of 1:37 p.m. EDT. There wasn't any company-specific news for Salesforce, but the entire enterprise software segment was down harshly today. This was likely due to a new update to Anthropic's agentic tool, which can now complete tasks on one's computer. The fear is that AI companies like Anthropic may be able to build agents that can displace some or all of the functionality that enterprise software companies provide today. Continue reading
Palantir Technologies Inc. Chief Technology Officer Shyam Sankar said that the war in Iran will likely be remembered as the first major conflict where artificial intelligence played a central role, representing a turning point in modern warfare. “Obviously current operations are ongoing, but people will reflect back and say this is the first large-scale combat operation that was really driven, enh...
Palantir Technologies Inc. Chief Technology Officer Shyam Sankar said that the war in Iran will likely be remembered as the first major conflict where artificial intelligence played a central role, representing a turning point in modern warfare. “Obviously current operations are ongoing, but people will reflect back and say this is the first large-scale combat operation that was really driven, enhanced and made substantially more productive with technology, with AI,” Sankar said in an interview on Bloomberg TV Tuesday. Sankar spoke from the sidelines of the Hill and Valley Forum , an annual confab in Washington for tech leaders and policymakers to discuss ways to maintain the US lead in artificial intelligence. This year’s event has been overshadowed by the war on Iran, where US forces have turned to a range of AI tools. Among the AI tech used in the Iran campaign is Palantir’s Maven Smart System, a digital mission control platform that manages enormous amounts of incoming data to speed decision-making. Maven was recently designated by defense officials as a program of record, a classification that will help ensure steady funding and development. AI’s role in helping select battlefield targets has drawn increased scrutiny, after Anthropic PBC ’s relationship with the Pentagon deteriorated partly due to concerns about fully autonomous weapons — a nontechnical term meaning arms that can select and destroy targets on their own. Read More: America’s Decade-Long AI War Efforts Get a Trial by Fire in Iran Sankar compared the role of technology in improving the efficiency of targeting to improving other processes like value chain management — a process that often takes months but can be faster. “The word targeting to the lay public has some sort of connotation, it sounds like someone’s shooting,” Sankar said. “But it’s actually a very bureaucratic, large-scale doctrinal process.” Palantir uses Anthropic’s Claude product in its Maven platform. That relationship has been sha...
Canada’s pensions have spent years betting that illiquid, private bets will yield superior returns. Lately, though, public markets have been doing the heavy lifting for them. Stock portfolios of at least four of Canada’s largest pension funds drove returns for three consecutive years, according to a Bloomberg analysis. A volatile yet resilient stock market spurred gains that exceeded private equit...
Canada’s pensions have spent years betting that illiquid, private bets will yield superior returns. Lately, though, public markets have been doing the heavy lifting for them. Stock portfolios of at least four of Canada’s largest pension funds drove returns for three consecutive years, according to a Bloomberg analysis. A volatile yet resilient stock market spurred gains that exceeded private equity returns as the asset class has yet to bounce back from a prolonged deal drought. At Ontario Teachers’ Pension Plan , public equities returned 15% last year while private equity posted its first loss since 2009. Ontario Municipal Employees Retirement System ’s stock holdings, meanwhile, returned 12% in 2025, as its buyout portfolio also ended up in the red. And Caisse de Depot et Placement du Quebec ’s stock portfolio gained 18% last year while its private equity portfolio returned 2.3%. Stocks have delivered double-digit gains globally in recent years, defying repeated warnings of stretched valuations. While a small group of big tech companies have driven much of the US rally, public equities have outperformed more broadly: Canada’s S&P/TSX Composite Index and Japan’s Nikkei each climbed more than 25% last year. Since the 2008 financial crisis, Canadian pension funds piled into private equity, infrastructure and real estate in search of higher returns. But that strategy left them underexposed to a prolonged rally in global stocks, just as private markets became crowded, expensive and difficult to exit. “Most allocators have relied on this idea that private markets would generate an illiquidity premium on top of the returns in public markets,” Eduard van Gelderen , the former chief investment officer of the Public Sector Pension Investment Board , said in an email. “This is clearly not the case.” Private equity has been in a rut since 2022, as higher borrowing costs slowed dealmaking and curtailed cash distributions to investors. By contrast, public markets have surged, wi...